Dyadic International, Inc. Lytham Partners Fall 2026 Investor Conference

Good day, everyone, and thank you for joining us today for the Lytham Partners Fall 2026 Investor Conference. My name is Joe Dorame, Managing Partner at Lytham Partners. I would like to welcome Dyadic Applied BioSolutions, which trades on the Nasdaq under the ticker DYAI. Today, Joe Hazelton, President and Chief Operating Officer, will be taking us through the company's presentation. Let's get started. Welcome, Joe.

Thank you, Joe, and thank you everyone for joining us today. I am excited to talk to everyone because it really is about Dyadic entering the commercial stage, where now we have multiple products entering the market across multiple segments utilizing our gene expression technology that we have developed over the last 30 years. Obviously, I will be making some forward-looking statements today. Please refer to our guidance in the SEC documents on our website. We are at the right place at the right time. As the world continues to expand, not just in terms of population growth, but also in terms of the demand for protein for therapeutics, for food and nutrition, or for bioindustrial, the expectation is that proteins need to be more scalable, more sustainable, and higher quality as they move towards commercialization. There are broader applications for which non-animal protein or non-animal solutions are being sought.

We are really at the right place at the right time because we have an industrially proven platform that we have been using for the last 30 years to produce proteins and enzymes for a variety of markets. Now we are applying that technology for real-world solutions across our three core business segments: life sciences, food nutrition, and bioindustrial. So we are really helping to meet the growing need for proteins worldwide, utilizing our highly productive and low-cost gene expression technology to produce these non-animal solutions. Now, what makes Dyadic a great opportunity right now is that we have moved from platform development to actually commercial execution. For the first time since prior to our sale to DuPont in 2015, we now have products commercially available on the market, both through our own distribution networks as well as our partners that are launching products into the market.

Today, I am going to focus in mainly on life sciences because that is where we see the most near-term revenues coming from. We have current products available like DNase I. It is a molecular biology reagent used in cell and gene therapy, diagnostics. It even is used to clean medical equipment. Then we have cell culture media products like albumin, transferrin, and growth factors. I will talk a little bit more about those in a minute. But we are coupling that with a global distribution network. We signed an agreement earlier this year with Integrated BioTherapeutics, and today they have six different products that are manufactured utilizing our gene expression technology currently on the market, and you can go to their website and look at those, but you will see DNase I, you will see transferrin, you will see growth factors, you will see alpha-lactalbumin. We have also been able to diversify our revenue models.

Now we're not just relying on licensing or grant revenues. We're actually starting to see initial product sales. We still have the opportunity to do licensing and obviously bring in milestones, and we have partnerships like with Proliant Health & Biologicals or with Inzymes that are now starting to yield commercial sales, and again, that will turn into recurring revenues for us. We are not just a one-trick pony anymore. We're not just trying to focus in on one single way to make money. We now have the ability to have multiple revenue models to hopefully improve our revenue outlook in the near term and accelerate to the future. Even though we're going to talk about life sciences, food nutrition, and bioindustrial, and it seems like we're focused on a lot of different areas, what we do remains the same for every project.

We utilize our proprietary fungal expression platforms to produce, scale, and ultimately commercialize products. That's basically what we do for every single project, no matter whether it's life sciences or bioindustrial. Now, we have two different platforms that we use to focus on multiple opportunities. We have our C1 platform. Those are more for highly complex or high-value proteins in life sciences and biopharma. We have our Dapibus platform that's optimized for the higher yield and the low-cost production of food, nutrition, and bioindustrial proteins, where these are more margin-sensitive markets. This really enables us to enter into these large volume markets where C1 is more for the complex, lower volume, but highly valued segments. As I mentioned before, we have multiple paths now to commercial revenues. We're currently selling products directly to different suppliers and distributors. Again, we're in the sampling process.

People are testing the products, and we expect to see recurring revenues start to generate. We also have our global distribution network set up through Integrated BioTherapeutics, and as I mentioned before, they currently have multiple products made in our expression systems on their website right now selling into the markets. We have the ability to license the strains that we produce, like we have with Inzymes. We've licensed bovine chymosin. Now they've commercialized that, and they're actually selling bovine chymosin commercially in the food space, the food and nutrition space. Then we have partnership opportunities where we have profit-sharing arrangements like we have with Proliant Health & Biologicals. Proliant is probably one of the largest suppliers of naturally derived albumin in the world. They have a global distribution network, they have a global customer base, and now they have their first non-animal protein.

They're selling recombinant human albumin, which is called AlbuFree DX. They also announced earlier this year that they're going to be launching two additional versions to target cell and gene therapy and cell culture media markets. So they're currently out there in the research space, quickly followed on by two additional products, all recombinant human albumin based, all utilizing our gene expression technology and targeting these rapidly growing markets. These are the ways that we're commercializing, and these are the ways that we're driving revenue for our shareholders. Now, we're focusing in on specific areas in each of our core verticals. In life sciences, we're focused on cell culture media and DNA and RNA molecular biology reagents.

The reason we are focusing in on those markets is that they are growing extremely fast with cell and gene therapy, the improved diagnostic capabilities out there, and things like monoclonal antibodies. To grow CHO cells to produce monoclonal antibodies, you need things like albumin, transferrin, and growth factors. Interestingly enough, these are also things that are used in other markets like cultured meat, use the same thing to grow animal muscle cells. The DNA and RNA molecular biology reagents like DNase I.